SCHEMBL30848862

SCHEMBL30848862

C=CCOC(=O)NCC(CC)c1cc(=O)oc2cc(O)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 4/20 0.46
HSD17B3 P37058 4/20 0.43
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 5/20 0.43
GLA P06280 3/20 0.43
GAA P10253 3/20 0.43
HPGD P15428 3/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 2/20 0.43
CYP1A2 P05177 2/20 0.43
MEN1 O00255 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 2/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C19 P33261 1/20 0.43
AKR1B1 P15121 4/20 0.39
HSD17B10 Q99714 2/20 0.39
ERAP1 Q9NZ08 1/20 0.39
CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30848898 0.88 ERN1 (0.47) ERN1HSD17B3KDM4EALDH1A1GLA
SCHEMBL30848924 0.83 ERN1 (0.66) ERN1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL16197852 0.82 HSD17B3 (0.51) HSD17B3KDM4EALDH1A1GLAGAA
SCHEMBL28328438 0.78 HSD17B3 (0.63) HSD17B3KDM4EALDH1A1GLAGAA
SCHEMBL17619213 0.76 ERN1 (0.68) ERN1HSD17B3KDM4EALDH1A1GLA
SCHEMBL17601907 0.74 HSD17B3 (0.44) HSD17B3KDM4EALDH1A1GLAGAA
SCHEMBL30848910 0.71 ERN1 (0.68) ERN1KDM4EALDH1A1GLAGAA
SCHEMBL16197957 0.69 HSD17B3 (0.52) HSD17B3KDM4EALDH1A1GLAGAA
SCHEMBL29785167 0.67 HSD17B3 (0.63) HSD17B3KDM4EALDH1A1GLAGAA
SCHEMBL18986303 0.67 HSD17B3 (0.63) HSD17B3KDM4EALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294487-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2024-09-05 US disclosed
US-11945789-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2024-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11945789-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof XBP1, DDIT3, ERN1 ERN1 3/4885HSD17B3 2599/4885KDM4E 2616/4885
US-20240294487-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF XBP1, DDIT3, ERN1 ERN1 3/4885HSD17B3 2599/4885KDM4E 2616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.